drugset / Trial / NCT01937130
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
RandomizedParallel-groupTriple-blindTreatment
Summary
The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.
Timeline
- Start
- 2013-09
- Primary completion
- 2015-01
- Completion
- 2015-02
Outcome
Outcome not reported
Stopped: “Data needs met”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emricasan | Small molecule | 5 mg | — |
| Subject | Emricasan | Small molecule | 25 mg | — |
| Subject | Emricasan | Small molecule | 50 mg | — |